Miiskin Competitors

DermTech 2.0 provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker platform technology. DermTech 2.0 develops and markets products to facilitate the assessment of melanoma, including the DermTech Melanoma Test, and offers DermTech Stratum, a precision biomarker service offering for biopharmaceutical and research partners.

Did you know that 1 in 5 people can develop skin cancer during their lifetime? While being one of the most prevalent types of cancer, if caught in time, skin cancer has the highest success rate in treatment and recovery. The timely reaction makes regular and reliable self-skin exams essential. With over 3 million users worldwide, SkinVision provides a medical service that democratizes access to reliable, convenient and accurate detection of risk of the most common types of skin cancer, helping to bring the right people in front of the healthcare practitioner in time for successful treatment. Empowered by a highly accurate AI-based algorithm, our app combines cutting-edge technology with best-in-class dermatologists expertise and support. SkinVision is clinically validated and can detect signs of most common skin cancers with 95% sensitivity. At SkinVision, we are continuously expanding our ecosystem. Together we are focused on taking skin health care to the next level, creating the highest patient-doctor value and eradicating skin cancer mortality worldwide. We are on a mission of saving the lives of 250.000 people in the next decades. If you share our vision and would like to become a SkinVision partner, write to us at partners@skinvision.com. Want to join us on this incredible journey and be a part of our dynamic team, check out our careers page https://skinvision1.recruitee.com/

EPISKIN SA, world pioneerin tissue engineering, is partnering with cosmetical, pharmaceutical, chemical industries to develop relevant and reliable safety and efficacy tests for decision making during research and development phases. Some screening tests are referenced and validated as alternatives to animal use, others are in the process of validation. Developed since 1992, their unique cell culture process allows to mass produce in vitro reconstructed human tissues with well characterized histology, functionality and ultrastructure features. The production unit is geared to serve every week our clients with thousands of human tissues.